Stratifying hypoglycaemic event risk in insulin-treated diabetes

The potential of individuals with diabetes to develop hypoglycaemia during insulin treatment presents a possible risk to them and others in certain safety-critical tasks, such as driving. Restrictions for insulin-treated drivers may limit this risk, but the evidence upon which such restrictions are based is limited. Prior epidemiological and pathophysiological evidence suggests that individuals with Type 2 diabetes in the early stages of insulin treatment may be: 1. at no greater risk of hypoglycaemia than individuals with Type 2 diabetes treated with sulphonylureas; 2. prone to less severe or less frequent periods of hypoglycaemia compared people with Type 1 diabetes. A prospective study, measuring the frequency and type of hypoglycaemia in different groups of individuals with diabetes was conducted to test these two hypotheses. This study used self-reported hypoglycaemia (measured by questionnaires) and continuous glucose monitoring to record episodes of hypoglycaemia over 9-12 months for people with both Type 1 and Type 2 diabetes.


  • English

Media Info

  • Pagination: 70p
  • Serial:
    • Issue Number: 61

Subject/Index Terms

Filing Info

  • Accession Number: 01388760
  • Record Type: Publication
  • Source Agency: ARRB
  • ISBN: 190476357X
  • Files: ATRI
  • Created Date: Aug 23 2012 1:16AM